12 Health Care Stocks Moving In Friday's Pre-Market Session
Actuate Therapeutics, Inc. +7.74%
AN2 Therapeutics, Inc. +0.12%
Corvus Pharmaceuticals, Inc. -0.06%
Enveric Biosciences, Inc. +34.20%
Harvard Bioscience, Inc. +0.50%
Actuate Therapeutics, Inc. ACTU | 2.73 | +7.74% |
AN2 Therapeutics, Inc. ANTX | 4.29 | +0.12% |
Corvus Pharmaceuticals, Inc. CRVS | 16.01 | -0.06% |
Enveric Biosciences, Inc. ENVB | 5.39 | +34.20% |
Harvard Bioscience, Inc. HBIO | 6.81 | +0.50% |
Gainers
- Psyence Biomedical (NASDAQ:PBM) stock rose 77.2% to $10.4 during Friday's pre-market session. The company's market cap stands at $6.0 million.
- iSpecimen (NASDAQ:ISPC) stock rose 34.76% to $0.16. The company's market cap stands at $3.4 million.
- Corvus Pharmaceuticals (NASDAQ:CRVS) shares increased by 14.69% to $17.25. The company's market cap stands at $1.2 billion.
- AN2 Therapeutics (NASDAQ:ANTX) shares increased by 14.33% to $3.59. The company's market cap stands at $112.8 million.
- Kura Oncology (NASDAQ:KURA) shares rose 12.75% to $10.08. The company's market cap stands at $793.5 million.
- Beyond Air (NASDAQ:XAIR) shares moved upwards by 12.33% to $0.5. The market value of their outstanding shares is at $4.6 million.
Losers
- Enveric Biosciences (NASDAQ:ENVB) shares fell 16.2% to $1.97 during Friday's pre-market session. The company's market cap stands at $3.2 million.
- Harvard Bioscience (NASDAQ:HBIO) stock fell 10.16% to $5.31. The market value of their outstanding shares is at $26.4 million.
- Trevi Therapeutics (NASDAQ:TRVI) shares declined by 8.88% to $13.25. The company's market cap stands at $1.8 billion.
- Actuate Therapeutics (NASDAQ:ACTU) shares fell 8.87% to $1.96. The market value of their outstanding shares is at $50.9 million.
- Propanc Biopharma (NASDAQ:PPCB) shares decreased by 8.0% to $0.1. The company's market cap stands at $2.3 million.
- Hoth Therapeutics (NASDAQ:HOTH) stock declined by 7.43% to $0.69. The company's market cap stands at $14.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
